Summary Safety Review - Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors INVOKANA (canagliflozin) and FORXIGA (dapagliflozin) - Evaluation of a Potential Risk of Acute Kidney Injury (French, HTML)

View metadata and access the original French HTML file: Summary Safety Review - Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors INVOKANA (canagliflozin) and FORXIGA (dapagliflozin) - Evaluation of a Potential Risk of Acute Kidney Injury.

Format

HTML

Access

file-only

Publisher-reported update

2024-05-10

A safety review was done to evaluate the potential risk of acute kidney injury and the use of two SGLT2 inhibitors, Invokana (canagliflozin) or Forxiga (dapagliflozin). This issue was identified following new safety information received from the manufacturer of Invokana following the marketing of this product.

Access original file